(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
0.75% HKD 6.76
Live Chart Being Loaded With Signals
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally...
Stats | |
---|---|
Объем за сегодня | 39.72M |
Средний объем | 39.90M |
Рыночная капитализация | 80.28B |
EPS | HKD0 ( 2024-03-19 ) |
Дата следующего отчета о доходах | ( HKD0.150 ) 2024-05-22 |
Last Dividend | HKD0.140 ( 2023-09-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 12.75 |
ATR14 | HKD0.00900 (0.13%) |
Объем Корреляция
CSPC Pharmaceutical Group Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
CSPC Pharmaceutical Group Корреляция - Валюта/Сырье
CSPC Pharmaceutical Group Финансовые показатели
Annual | 2023 |
Выручка: | HKD34.75B |
Валовая прибыль: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2023 |
Выручка: | HKD34.75B |
Валовая прибыль: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2022 |
Выручка: | HKD35.98B |
Валовая прибыль: | HKD25.88B (71.94 %) |
EPS: | HKD0.590 |
FY | 2021 |
Выручка: | HKD27.87B |
Валовая прибыль: | HKD21.14B (75.84 %) |
EPS: | HKD0.470 |
Financial Reports:
No articles found.
CSPC Pharmaceutical Group Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.110 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0365 | 2003-08-28 |
Last Dividend | HKD0.140 | 2023-09-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | HKD1.673 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.25 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.59 | |
Div. Directional Score | 8.48 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3958.HK | Ex Dividend Junior | 2023-05-23 | Annually | 0 | 0.00% | |
1773.HK | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
0816.HK | No Dividend Player | 2023-06-12 | Insufficient data to determine frequency | 0 | 0.00% | |
2359.HK | Ex Dividend Knight | 2023-06-05 | Annually | 0 | 0.00% | |
1336.HK | Ex Dividend Junior | 2023-07-06 | Annually | 0 | 0.00% | |
0386.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
6668.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
1890.HK | Ex Dividend Knight | 2023-08-04 | Annually | 0 | 0.00% | |
0916.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
0038.HK | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.189 | 1.500 | 6.23 | 9.34 | [0 - 0.5] |
returnOnAssetsTTM | 0.150 | 1.200 | 5.01 | 6.01 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.62 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.533 | -1.000 | 4.67 | -4.67 | [0 - 1] |
currentRatioTTM | 2.63 | 0.800 | 1.867 | 1.494 | [1 - 3] |
quickRatioTTM | 2.27 | 0.800 | 1.336 | 1.069 | [0.8 - 2.5] |
cashRatioTTM | 1.180 | 1.500 | 4.56 | 6.83 | [0.2 - 2] |
debtRatioTTM | 0.0151 | -1.500 | 9.75 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 362.23 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.701 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.369 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0210 | -1.500 | 9.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.707 | 1.000 | 1.551 | 1.551 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.232 | 1.000 | 7.36 | 7.36 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.82 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.794 | 0.800 | 8.04 | 6.43 | [0.5 - 2] |
Total Score | 11.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.49 | 1.000 | 9.04 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.11 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.369 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.70 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.701 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.533 | 1.500 | 4.67 | -4.67 | [0 - 1] |
pegRatioTTM | -0.257 | 1.500 | -5.04 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.205 | 1.000 | 7.37 | 0 | [0.1 - 0.5] |
Total Score | 5.59 |
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа